Carol Lefevre stumbled on tai chi while recovering from cancer, and after losing her mother and her aunt. It transformed her ...

Drug candidates spanning oncology, neurology, rare diseases and more are approaching critical development as the calendar turns to 2026.

Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

The authors describe an interesting approach to studying the dynamics and function of membrane proteins in different lipid environments. The important findings have theoretical and practical ...

Analyst/Investor Day October 16, 2025 9:00 AM EDTCompany ParticipantsCleo Palmer-PoronerWilliam Marshall - Co-Founder, CEO ...

Infrastructure experts, government officials, academics, and development practitioners, have stressed the urgent need for Africa to integrate women’s voices in infrastructure delivery, warning that ...

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...

Subscribe Login Register Log out My Profile Subscriber Services Search EBLADE ENTER-TO-WIN BLADE REWARDS BLADE VAULT / REPRINTS OBITUARIES JOBS CLASSIFIEDS BLADE HOMES HOMES WEEKLY ADS EVENTS CONTACT ...